Abstract
As p53 and its homologue p73 have significant sequence and functional similarities, p73 might also be expected to act as a tumour suppressor. However, p73 is activated after DNA damage in a way that is distinct from that of p53. The existence of ΔNp73 - an isoform of p73 that is encoded by a distinct promoter and that lacks the transactivation domain - further complicates matters. It seems to function as an oncogene by inhibiting both p73- and p53-induced apoptosis. So how can these opposing functions be reconciled in human tumours?
Original language | English |
---|---|
Pages (from-to) | 605-615 |
Number of pages | 11 |
Journal | Nature Reviews Cancer |
Volume | 2 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2002 |
ASJC Scopus subject areas
- Cancer Research